ClinicalTrials.gg
TerminatedNCT05784129PROGRESSUpdated Apr 29, 2025Results posted

A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection

A Phase 3 interventional study of Guselkumab and Placebo in Crohn's Disease, sponsored by Janssen Research & Development, LLC. Terminated at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Why this study was terminated
Janssen made an internal business decision to discontinue the PROGRESS study. This decision is not related to any efficacy or safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing guselkumab in Crohn Disease — 6 open to participants now, 11 under way, 7 of them phase 3. guselkumab · Crohn Disease.

Enrollment
13th of 13
4 · median 196
Started
2023
the only one that year
Phase 3
8 of 13
3 open now
Registered
6th of 13
by date
Lead sponsor
8 of 13
Janssen Research & Development, LLC

Among the 13 studies testing guselkumab in Crohn Disease, this one is the 13th largest by enrollment, is the only one that started in 2023, is one of 8 in phase 3, and was the 6th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

6 of the 13 studies testing guselkumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About guselkumab

guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing guselkumab in Crohn Disease, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness of guselkumab treatment compared with placebo (an inactive substance with no medicine) in preventing recurrence of Crohn's disease in participants after surgery.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Endoscopy, Postoperative, Ileocolonic resection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a documented diagnosis of Crohn's disease (CD) confirmed by endoscopic, histologic, and/or radiologic studies prior to resection or by tissue obtained at resection
  • Have undergone an ileocolonic surgical resection (that is, an intestinal resection with an ileocolonic anastomosis) for CD prior to the baseline visit with the following criteria: (a)Have no known active CD anywhere in the gastrointestinal (GI) tract, including the findings at surgery. (b)Be able to undergo randomization no later than 49 days after surgery, and at least 10 days after surgery (or 8 days after resumption of bowel activity, example, in case of postoperative ileus) (c) Ileocolonic resection was not for the purpose of removing known dysplasia. (d) If ileocolonic resection is the participant's first resection for Crohn's, and occurs greater than (>) 10 years since the diagnosis of CD and only fibrostenotic stricturing is present, then length of stricture must be > 10 centimeter (cm)
  • Have a baseline Crohn's Disease Activity Index (CDAI) less than (\<) 200
  • A woman of must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) test result during screening and a negative urine pregnancy test at week 0, prior to randomization
  • A woman must agree not to donate eggs (ova, oocytes) or freeze for future use for the purposes of assisted reproduction during the study and for a period of 12 weeks after the last administration of study intervention

Exclusion criteria

Exclusion Criteria:

  • Has complications of CD, such as symptomatic strictures or stenoses, short bowel syndrome, a draining (that is, functioning) stoma or ostomy, or any other manifestation, that might be anticipated to require surgery, could preclude the use of the CDAI to assess response to therapy, or would possibly confound the ability to assess the effect of treatment with guselkumab
  • Currently has or is suspected to have an abscess. Recent cutaneous and perianal abscesses are not exclusionary if drained and adequately treated at least 3 weeks before baseline, or 8 weeks before baseline for intra-abdominal abscesses, provided that there is no anticipated need for any further surgery
  • Have had any active perianal disease within 3 months of screening (except skin tags) or have had any draining fistula within 3 months of screening unless the fistula was removed at the index surgery
  • Evidence of a herpes zoster infection within 8 weeks before the first dose of study intervention
  • Has a history of severe, progressive, or uncontrolled renal, genitourinary, hematologic, endocrine, cardiac, vascular, pulmonary, rheumatologic, neurologic, psychiatric, or metabolic disturbances, or signs and symptoms thereof
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
4 participants (actual)

Study arms

  • Active comparator
    Group 1: Guselkumab

    Participants will receive Guselkumab Dose 1 subcutaneously (SC) followed by Dose 2 SC thereafter through Week 144. Participants with disease recurrence will receive guselkumab SC treatment.

    Drug: Guselkumab

  • Placebo comparator
    Group 2: Placebo

    Participants will receive matching placebo injections subcutaneously. Participants with disease recurrence will receive guselkumab SC treatment.

    Drug: Placebo

Interventions

  • Guselkumab will be administered subcutaneously.

    Also known as: CNTO1959

  • DrugPlacebo

    Placebo will be administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Endoscopic Recurrence Prior to or at Week 48

    Endoscopic recurrence was defined by modified Rutgeerts score greater than or equal to (\>=) i2a in neo-terminal ileum, anastomotic site, or its equivalent in gastrointestinal (GI) tract (e.g., colonic ulceration). The modified Rutgeerts score ranged from i0 to i4, where i0 (No lesions), i1 (less than \[\<\] 5 aphthous lesions), i2 (greater than \[\>\] 5 aphthous lesions with normal mucosa between lesions or skip areas of larger lesions or lesions confined to ileocolonic anastomosis \[\<1 centimeter (cm) in length\]), i2a (lesions confined to ileocolonic anastomosis \[including anastomotic stenosis\]), i2b (more than 5 aphthous ulcers or larger lesions, with normal mucosa in-between, in the neoterminal ileum \[with or without anastomotic lesions\]), i3 (diffuse aphthous ileitis with diffusely inflamed mucosa), i4 (large ulcers with diffuse mucosal inflammation or nodules or stenosis in neoterminal ileum). Higher score indicated worsening.

    Time frame: Baseline (Day 1) up to Week 48

Secondary outcomes

  1. Percentage of Participants With Clinical Remission Without Disease Recurrence at Week 48

    Clinical remission without disease recurrence at Week 48 was a composite endpoint defined by (1) Crohn's disease activity index (CDAI) \<150 at Week 48 \& (2) no endoscopic recurrence as defined by modified Rutgeerts score \< i2a by Week 48 \& (3) have not experienced disease recurrence. Disease recurrence was defined as (1) \>=70 point increase from baseline in CDAI score at \>8 weeks after randomization \& CDAI score \>=200 and evidence of endoscopic recurrence (Rutgeerts score \<i2a) or (2) initiation of physician-prescribed corticosteroids or increase in steroid dose of \>5 milligrams per day (mg/day) for treatment of Crohn's disease (CD) and endoscopic recurrence or (3) new draining or reopening of an internal or external fistula or (4) new perianal abscess or (5) new intra-abdominal abscess more than 3 months post index surgery. If a patient tested positive for enteric pathogen, infection should be treated and then participant should be reassessed for whether they meet disease recurrence.

    Time frame: At Week 48

  2. Time to Disease Recurrence

    Disease recurrence was defined by (1) a \>=70 point increase from baseline in CDAI score at \>8 weeks after randomization \& CDAI score \>=200 and evidence of endoscopic recurrence (Rutgeerts score \<i2a) or (2) initiation of physician-prescribed corticosteroids or increase in steroid dose of \>5 milligrams per day (mg/day) for treatment of Crohn's disease (CD) and endoscopic recurrence or (3) new draining or reopening of an internal or external fistula or (4) new perianal abscess or (5) new intra-abdominal abscess more than 3 months post index surgery. If a patient tested positive for enteric pathogen, infection should be treated and then participant should be reassessed for whether they meet disease recurrence.

    Time frame: Baseline (Day 1) up to Week 48

  3. Percentage of Participants With No Abdominal Pain at Week 48

    Abdominal pain free at Week 48 is defined as abdominal pain (AP) score = 0 at Week 48. The scoring was done on a 4-point scale, ranged from 0 to 3, where 0 equals none, 1 equals mild, 2 equals moderate and 3 equals severe pain. Higher score indicated severe pain.

    Time frame: At Week 48

  4. Time To Recurrence of Symptoms

    Time-to-recurrence of symptoms was defined as time to attaining an AP mean daily score \>1 (and also \>1 point higher than baseline) along with stool frequency (SF) mean daily score \>3 (and also \>3 higher per day than baseline) for 2 consecutive weeks through Week 48. AP score scaling was done on a 4-point score scale, ranged from 0 to 3, where 0 equals none, 1 equals mild, 2 equals moderate and 3 equals severe pain. Higher score indicated severe pain. Stool frequency score was calculated from the total number of liquid or very soft stools in the previous 7 days.

    Time frame: Baseline (Day 1) up to Week 48

  5. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

    Number of participants with TEAEs and TESAEs were reported. An adverse event (AE) was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE/SAE occurring at or after the initial administration of study intervention through early termination of trial (up to Week 28) was considered to be treatment emergent.

    Time frame: Baseline (Day 1) up to early termination of trial (up to Week 28)

  6. Serum Guselkumab Concentrations Over Time

    Serum guselkumab concentrations over time were reported. No summary analysis was done as study was terminated early and participant wise data were reported. This outcome measure was planned to be analyzed for "Guselkumab 200 mg + Guselkumab 100 mg" arm only.

    Time frame: At Weeks 0, 8, 16

  7. Percentage of Participants With Steroid Free Clinical Remission at Week 48

    Steroid free clinical remission at Week 48 is defined as CDAI \<150 and no corticosteroids within 30 days. The CDAI was a validated multi-item measure of severity of illness derived as a weighted sum of 8 different Crohn's disease-related variables. The CDAI score was assessed by collecting information on 8 different Crohn's disease-related variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain/cramping, use of antidiarrheal drug(s), and/or opiates, and general well-being. The last 4 variables were scored over 7 days by the participant on a diary card. In general, CDAI score ranges from 0 to approximately 600; higher score indicated higher disease activities.

    Time frame: At Week 48

07

Results

Posted Oct 28, 2024
Limitations and caveats
Due to early termination of study, protocol planned primary endpoint and few of secondary endpoints were not evaluable. Termination was not related to safety or efficacy of guselkumab.

Participant flow

A total of 4 participants who had recently undergone a surgical resection for Crohn's Disease (CD) were enrolled, randomized (1:1) and treated with study drug or placebo.

Participant flow — Overall Study
MilestoneGuselkumab 200 mg + Guselkumab 100 mgPlacebo
Started22
Treated at weeks 0, 8 and 1612
Treated at weeks 0, 810
Completed00
Not completed22
Withdrew: Study terminated by sponsor22

Outcome measures

PrimaryPercentage of Participants With Endoscopic Recurrence Prior to or at Week 48

Endoscopic recurrence was defined by modified Rutgeerts score greater than or equal to (\>=) i2a in neo-terminal ileum, anastomotic site, or its equivalent in gastrointestinal (GI) tract (e.g., colonic ulceration). The modified Rutgeerts score ranged from i0 to i4, where i0 (No lesions), i1 (less than \[\<\] 5 aphthous lesions), i2 (greater than \[\>\] 5 aphthous lesions with normal mucosa between lesions or skip areas of larger lesions or lesions confined to ileocolonic anastomosis \[\<1 centimeter (cm) in length\]), i2a (lesions confined to ileocolonic anastomosis \[including anastomotic stenosis\]), i2b (more than 5 aphthous ulcers or larger lesions, with normal mucosa in-between, in the neoterminal ileum \[with or without anastomotic lesions\]), i3 (diffuse aphthous ileitis with diffusely inflamed mucosa), i4 (large ulcers with diffuse mucosal inflammation or nodules or stenosis in neoterminal ileum). Higher score indicated worsening.

Time frame:
Baseline (Day 1) up to Week 48

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Clinical Remission Without Disease Recurrence at Week 48

Clinical remission without disease recurrence at Week 48 was a composite endpoint defined by (1) Crohn's disease activity index (CDAI) \<150 at Week 48 \& (2) no endoscopic recurrence as defined by modified Rutgeerts score \< i2a by Week 48 \& (3) have not experienced disease recurrence. Disease recurrence was defined as (1) \>=70 point increase from baseline in CDAI score at \>8 weeks after randomization \& CDAI score \>=200 and evidence of endoscopic recurrence (Rutgeerts score \<i2a) or (2) initiation of physician-prescribed corticosteroids or increase in steroid dose of \>5 milligrams per day (mg/day) for treatment of Crohn's disease (CD) and endoscopic recurrence or (3) new draining or reopening of an internal or external fistula or (4) new perianal abscess or (5) new intra-abdominal abscess more than 3 months post index surgery. If a patient tested positive for enteric pathogen, infection should be treated and then participant should be reassessed for whether they meet disease recurrence.

Time frame:
At Week 48

No measurements were reported for this outcome.

SecondaryTime to Disease Recurrence

Disease recurrence was defined by (1) a \>=70 point increase from baseline in CDAI score at \>8 weeks after randomization \& CDAI score \>=200 and evidence of endoscopic recurrence (Rutgeerts score \<i2a) or (2) initiation of physician-prescribed corticosteroids or increase in steroid dose of \>5 milligrams per day (mg/day) for treatment of Crohn's disease (CD) and endoscopic recurrence or (3) new draining or reopening of an internal or external fistula or (4) new perianal abscess or (5) new intra-abdominal abscess more than 3 months post index surgery. If a patient tested positive for enteric pathogen, infection should be treated and then participant should be reassessed for whether they meet disease recurrence.

Time frame:
Baseline (Day 1) up to Week 48

No measurements were reported for this outcome.

SecondaryPercentage of Participants With No Abdominal Pain at Week 48

Abdominal pain free at Week 48 is defined as abdominal pain (AP) score = 0 at Week 48. The scoring was done on a 4-point scale, ranged from 0 to 3, where 0 equals none, 1 equals mild, 2 equals moderate and 3 equals severe pain. Higher score indicated severe pain.

Time frame:
At Week 48

No measurements were reported for this outcome.

SecondaryTime To Recurrence of Symptoms

Time-to-recurrence of symptoms was defined as time to attaining an AP mean daily score \>1 (and also \>1 point higher than baseline) along with stool frequency (SF) mean daily score \>3 (and also \>3 higher per day than baseline) for 2 consecutive weeks through Week 48. AP score scaling was done on a 4-point score scale, ranged from 0 to 3, where 0 equals none, 1 equals mild, 2 equals moderate and 3 equals severe pain. Higher score indicated severe pain. Stool frequency score was calculated from the total number of liquid or very soft stools in the previous 7 days.

Time frame:
Baseline (Day 1) up to Week 48

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

Number of participants with TEAEs and TESAEs were reported. An adverse event (AE) was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE/SAE occurring at or after the initial administration of study intervention through early termination of trial (up to Week 28) was considered to be treatment emergent.

Time frame:
Baseline (Day 1) up to early termination of trial (up to Week 28)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
ParticipantsGuselkumab 200 mg + Guselkumab 100 mgPlacebo
TEAEs11
TESAEs11
SecondarySerum Guselkumab Concentrations Over Time

Serum guselkumab concentrations over time were reported. No summary analysis was done as study was terminated early and participant wise data were reported. This outcome measure was planned to be analyzed for "Guselkumab 200 mg + Guselkumab 100 mg" arm only.

Time frame:
At Weeks 0, 8, 16
Reported as:
Number · micrograms/milliliters (ug/mL)
Serum Guselkumab Concentrations Over Time
micrograms/milliliters (ug/mL)Guselkumab 200 mg + Guselkumab 100 mg
Participant 1 (Week 0)0
Participant 1 (Week 8)1.68920
Participant 1 (Week 16)0.70957
Participant 2 (Week 0)0
Participant 2 (Week 8)2.87917
SecondaryPercentage of Participants With Steroid Free Clinical Remission at Week 48

Steroid free clinical remission at Week 48 is defined as CDAI \<150 and no corticosteroids within 30 days. The CDAI was a validated multi-item measure of severity of illness derived as a weighted sum of 8 different Crohn's disease-related variables. The CDAI score was assessed by collecting information on 8 different Crohn's disease-related variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain/cramping, use of antidiarrheal drug(s), and/or opiates, and general well-being. The last 4 variables were scored over 7 days by the participant on a diary card. In general, CDAI score ranges from 0 to approximately 600; higher score indicated higher disease activities.

Time frame:
At Week 48

No measurements were reported for this outcome.

Adverse events

Collected over Baseline (Day 1) up to 12 weeks after last study dose administration (up to Week 28). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Guselkumab 200 mg + Guselkumab 100 mg0/2 (0%)1/2 (50%)0/2 (0%)
Placebo0/2 (0%)1/2 (50%)0/2 (0%)
Most frequent serious events
Most frequent serious events
EventGuselkumab 200 mg + Guselkumab 100 mgPlacebo
Campylobacter GastroenteritisInfections and infestations0/21/2
NephrolithiasisRenal and urinary disorders1/20/2

Baseline characteristics

Analysis was performed on all randomized participants. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, data were reported under a single arm.

Age, Continuous
Age, Continuous(Years)Overall Participants
Mean46.3 ± 6.75
Age, Customized
Age, Customized(Participants)Overall Participants
Children (2-11 years)0
Adolescents (12-17 years)0
Adults (18-64 years)4
From 65 to 84 years0
85 years and over0
Sex: Female, Male
Sex: Female, Male(Participants)Overall Participants
Female2
Male2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Participants
Hispanic or Latino0
Not Hispanic or Latino0
Unknown or Not Reported4
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall Participants
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White3
More than one race0
Unknown or Not Reported1
08

Study locations

11 sites
  • Medical Associates Research Group, Inc.
    San Diego, California 92123, United States
  • Gastroenterology Group Of Naples
    Naples, Florida 34102, United States
  • Gastroenterolgy Associates of Central GA
    Macon, Georgia 31201, United States
  • Louisiana Research Center, LLC
    Shreveport, Louisiana 71105, United States
  • Asheville Gastroenterology Associates
    Asheville, North Carolina 28801, United States
  • Gastro Health Ohio
    Cincinnati, Ohio 45219, United States
  • Southern Star Research Institute, LLC
    San Antonio, Texas 78229, United States
  • Texas Digestive Disease Consultants
    Southlake, Texas 76092, United States
  • Tyler Research Institute, LLC
    Tyler, Texas 75701, United States
  • Centrum Medyczne Medyk
    Rzeszow, 35-326, Poland
  • WIP Warsaw IBD Point Profesor Kierkus
    Warszawa, 00-728, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Sep 2023, 7 months.

Results were first posted in Oct 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2023
First posted
Mar 24, 2023
StartActual
Feb 21, 2023
Primary completionActual
Sep 29, 2023
CompletionActual
Oct 10, 2023
Results first posted
Oct 28, 2024
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05784129
Responsible party
Sponsor
First posted
Mar 24, 2023
Start date
Feb 21, 2023
Primary completion
Sep 29, 2023
Completion
Oct 10, 2023
Results posted
Oct 28, 2024
Last update
Apr 29, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion